- Details
- Sam Chang and Jeffrey Holzbeierlein discuss the comparative effectiveness of neoadjuvant chemotherapy for bladder cancer, as well as for upper urinary tract urothelial carcinoma. Dr. Holzbeierlein goes into depth on the background of neoadjuvant treatment for these diseases, as well as a look at the POUT trial. They also discuss future projects and exciting new studies. Biographies: Jeffrey Holzbe...
|
- Details
- In this discussion with Sam Chang on the prevention of bladder recurrence, Aditya Bagrodia starts off with a case study of a 69-year-old female in generally good health, presents with hematuria, well-controlled diabetes, hypertension, remote history of smoking, and importantly, no history of upper tract urothelial cancer in the family or other Lynch syndrome-associated malignancies. Drs. Bagrodia...
|
- Details
- Kyle Rose, SUO Clinical Fellow at Moffitt Cancer Center joins Alicia Morgans in highlighting his AUA presentation on the real-world data on the antegrade administration of reverse thermal mitomycin (JEMLYTO®) for primary chemoablation of upper tract urothelial carcinoma (UTUC). Based on results from the pivotal OLYMPUS trial, JELMYTO® is currently approved for low-grade UTUC. Dr. Rose and colleagu...
|
- Details
- Sam Chang invites Jean Hoffman-Censits to highlight the multidisciplinary work in upper tract urothelial carcinoma (UTUC) with a particular focus on patients that have high-grade UTUC being done at the Greenberg Bladder Cancer Institute at Johns Hopkins University, where Dr Hoffman-Censits is the co-director of the program. Drs. Chang and Hoffman-Censits discuss the current treatment landscape for...
|
- Details
- Ashish Kamat hosts Alexander Wyatt to discuss the role of circulating tumor DNA (ctDNA) in the clinical management of urothelial carcinoma, especially in metastatic cases. Dr. Wyatt highlights ctDNA's utility in cancer screening, residual disease detection, and therapy monitoring. Data indicates that higher levels of ctDNA often correlate with worse disease prognosis. The conversation also explore...
|
- Details
- In this UroToday Journal Club video presentation, Christopher Wallis and Zachary Klaassen review the Journal of Urology publication "Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report" led by Drs Surena Matin and Seth Lerner. The goal of this study was to evaluate the lo...
|
- Details
- Wesley Yip and Sam Chang discuss the results of a multicenter trial of neoadjuvant gemcitabine and cisplatin in patients with upper tract urothelial carcinoma (UTUC) presented at the ASCO GU 2022 Cancer Symposium. This phase II multicenter trial of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with high-risk UTUC prior to extirpative surgery sought to evaluate major outcomes...
|
- Details
- Surena Matin joins Sam Chang in a state-of-the-art lecture and discussion on endoscopic management of low-grade upper tract urothelial carcinoma. Dr. Matin highlights several established therapies for the treatment of low-grade upper tract urothelial carcinoma and the two discuss ongoing trials in this disease space. Biographies: Surena F. Matin, MD, Professor, Department of Urology, Division of S...
|
- Details
- Janet Kukreja joins Sam Chang to further highlight her presentation at GU ASCO 2022 focusing on clinical implications of molecular biomarkers in upper tract urothelial carcinoma (UTUC). Currently, the ideal marker does not exist, but we are on our way to more personalized medicine. Drs Chang and Kukreja highlight improved characterization, better identification, risk stratification, and then indiv...
|
- Details
- Sam Chang is joined by Katie Murray to discuss treatment options for low-grade upper-tract disease. As the treatment for this disease has evolved over time, Dr. Murray focuses her presentation on her practice and the nuts and bolts of how she treats upper tract urothelial carcinoma. Biographies: Katie S. Murray, DO, MS, FACS, Assistant Professor of Urologic Oncology, Medical Director-Ellis Fischel...
|
